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Meeting reportWhile there is agreement that quality of life (QoL) is a central aim of medical treatment, the methods of
its evaluation as well as its role in the patient’s overall treatment experience are under continuous
scrutiny. Different perspectives on patients’ QoL have emerged; from the treating physician, from the
psychologist, and naturally from the patient him/herself. This article provides insights into each of these
views within the context of thyroid cancer where, as a consequence of increasing incidence and decreas-
ing mortality rates, QoL aspects deserve close attention. Physicians often ﬁnd themselves in situations
where they perform a balancing act between what they know is best from a somatic point of view and
learning about what is best for the individual patient. For psychologists in the ﬁeld of oncology, a main
area of interest is the incorporation of the patient’s perspective into research by using patient-reported
outcomes (PROs) which include QoL assessment. PROs can also be used in clinical practice as a way to
start a conversation about symptoms and QoL aspects that perhaps patients might not volunteer, and this
allows physicians to address QoL issues more directly. Patients usually appreciate being asked about all
aspects of QoL, and need sound information about how their QoL might be affected by the disease and its
treatment. By examining and understanding the different perspectives on QoL, and how QoL differs in
patients with thyroid cancer compared with other cancers, it is hoped that the QoL can be enhanced in
this particular patient group.
 2015 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).Introduction
This paper summarises presentations and discussions from the
Quality of Life and Follow Up session of a physician-only meeting
held in Vienna, November 23, 2013 entitled Thyroid cancer: from
nodule to cure – the controversies. The meeting was organised by
the Austrian Society of Nuclear Medicine and Molecular Imaging
and the Medical University of Vienna. The session presented three
different perspectives on the QoL of thyroid cancer patients; those
of the treating physician, the psychologist, and the patient. QoL is
becoming an increasingly important issue but is difﬁcult to deﬁne
and address. Particularly in the case of thyroid cancer, the symp-
toms may have a broad range (from emotional to physical discom-
fort, depending on the thyroid hormone status), which can affect
the patient severely. The patient does not know what kind of
symptoms they may be facing and is often left alone with their
diagnosis and fears. Time pressure and the reluctance to ‘burden’
the physician with ‘emotional’ symptoms may silence the patient,
and the physician often only sees the favourable prognosis ofthyroid cancer compared with other cancer types and neglects to
address QoL issues. A speciﬁc questionnaire may help to bridge
these two perspectives and allow both sides to understand what
and where the patient’s discomforts are and what the physician
can do to relieve them. Some symptoms may last for a speciﬁc time
(e.g. hormonal withdrawal prior to ablative radioiodine treatment),
and explaining this would help the patient to understand and
accept the symptoms; or the situation could be avoided by using
a different form of treatment (e.g. by using recombinant TSH stim-
ulation). However, in Austria only a minority of patients receive
this kind of preparation for radioiodine treatment and this is
usually for thyroid remnant ablation. Therefore, the problems with
symptoms caused by hormone withdrawal are less signiﬁcant.
In the majority of patients, if it is considered that subsequent
therapeutic administration of radioiodine will not be required,
exogenous stimulation by recombinant human thyrotropin
(rhTSH) is used for diagnostic purposes. In cases where radioiodine
treatment may be required, some centres still prefer endogenous
stimulation for all patients. Additionally, some treatments e.g.
TSH-suppressive therapy after radioiodine treatment, can lead to
several symptoms such as palpitation, restlessness, and nervous-
ness, which may last for the rest of the patient’s life. Since thyroid
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psychologist may be invaluable to help the patient cope with their
symptoms. However, until the physician knows where the
patient’s discomforts are, they cannot be treated or managed.
The physician’s view – Dr. Alexander Becherer
The physician’s view of QoL in thyroid cancer patients can be
explained and explored by examining case studies.
The ﬁrst case presented was a 36 year-old female patient, with a
slightly painful nodule in the anterior neck, and who had been
showing symptoms for 1 month. Apart from a heart rate of
96 bpm, she was clinically euthyroid. On palpation, the nodule
was moveable, rather dense, and likely situated in the isthmus
on the left side. The physician’s ﬁrst assumption based on
anamnesis and clinical ﬁndings was that this was most likely a
cyst, and the patient was told that most of the nodules with this
history are benign. The patient was relieved and very happy.
However, ultrasound showed that it was not a cyst, but a
17 mm hypoechogenic nodule with irregular boundaries. As no
TSH level was known, scintigraphy with Tc-99 m pertechnetate
demonstrated that the lesion was cold. Thus, ﬁne needle aspiration
cytology (FNAC) was indicated. The patient was given the updated
news and was understandably very distressed.
The case illustrated that although it is better for patients (and
improves the quality of their experience) to be given a ﬁrm diagno-
sis as soon as possible, particularly if the diagnosis is a benign one,
this is often not possible based on statistical probabilities. The
physician should wait for the results of the whole bundle of
diagnostic tests because speculative diagnoses (even if statistically
probable) can lead to great distress once a different diagnosis is
made. However, in thyroid nodules scintigraphy can be done
immediately and gives a result very quickly, which is much better
for the patient than waiting for the thyrotropin result to determine
whether a nodule is hyper- or hypofunctioning.
Given the results of sonography and scintigraphy, the physi-
cian’s view was that the nodule had a signiﬁcant chance of being
a carcinoma. The patient was told that there was a 1 in 5 chance
of the nodule being cancer (to make her aware of the possibility
that she had a malignant disease, but without leaving her with a
very pessimistic outlook). Finally, FNAC revealed papillary thyroid
carcinoma. This highlighted the importance of not telling patients
their results in detail if there is a possibility of changing the
message. The patient underwent thyroidectomy a few days after
receiving the FNAC result. She had a PTC pT1bN1a tumour, maxi-
mum diameter of 17 mm, BRAF V600E mutated, with 6 out of 39
metastatic lymph nodes. Her response to surgery and radioiodine
ablation with 1850 MBq 131I under rhTSH stimulation was excel-
lent, with a stimulated thyroglobulin (Tg) of 0.5 ng/ml (IMMULITE
2000 XPi, Siemens Healthcare, Erlangen, Germany, analytic
sensitivity, 0.2 ng/ml) two months after radioiodine ablation.
In terms of QoL issues, the patient was concerned about her
small son, whether she would be able to see him grow up, and
whether he would lose his mother. She was also concerned about
her ability to have more children, and if the treatment for her can-
cer would mean that she would lose her hair. A key learning point
from this interaction was the importance of remembering that
although physicians may tell patients ‘You have a carcinoma with
an extremely favourable prognosis’, and try to make the most
memorable words for the patient ‘an extremely favourable prog-
nosis’, in fact the words that the patient mainly hears are only
‘you have a carcinoma’ [1].
The second case concerned a 74 year old female patient with a
14 year history of follicular thyroid carcinoma, pT4N0Mx. She had
6 diagnostic scans over 6 years and was in complete remission.
Then her Tg level started to rise, and the patient was treated withradioiodine therapy. Following treatment the patient received 2
check-ups per year. No detectable lesions were found either by
diagnostic scanning with 131Iodine, with 18F-FDG, or with ultra-
sound. However, her Tg levels continued to rise without any dis-
cernible clinical symptoms.
The QoL issues in this case centred around helping the patient
to accept that her Tg level was a laboratory ﬁnding which necessi-
tated more frequent check-up visits, but did not inﬂuence her
wellbeing. The patient had tooth problems with softening of
adamantine, caused by xerostomia (an adverse effect of radioio-
dine). Initially the patient did not want to spend any money on
her teeth because she believed ‘it’s not worth while investing
money on my teeth because I’m going to die soon.’ However, the
physician convinced her that the prognosis was good, and she
had her teeth repaired and was very proud of them. The patient
is currently in very good condition, is healthy, and enjoying life
with her husband and grandchildren.
The third case report was of a 61 year-old male patient, with
poorly differentiated follicular cancer pT4pT1Mx, that had relapsed
locally twice already in the early course of the disease. Eventually
he developed pulmonary metastases for which he underwent 3
operations on the right lung (ﬁrst 9 years after his ﬁrst diagnosis,
then again 1 year later, and ﬁnally a further year later). The patient
also underwent external radiotherapy for metastases in the left
lung. He had been treated for the last 2 years with a tyrosine kinase
inhibitor, which had slowed the progression of the cancer. The
patient had no symptoms from the lesions, but treatment with
sorafenib affected his QoL due to the development of severe
hand-foot-syndrome, and subsequent mild diarrhoea when he
switched his medication from sorafenib to pazopanib. However,
the hand-foot-syndrome resolved and the patient controlled his
diarrhoea during the day with other medication, and was able to
continue to work as a travelling salesman. The patient was very,
and would have not even attended his monthly check-ups if he
had not needed a new prescription for pazopanib and on the insis-
tence of his wife. She said that the main reason for her husband
missing the check-ups was his fear of receiving bad news. His main
complaints were diarrhoea, his hair becoming white, and a lack of
compliance with his antihypertension medicine.
In summary, although this patient had a severe, progressive
disease, he had an acceptable QoL. This is because he had different
coping strategies than those of the patient in case study 2 – illus-
trated by the fact that he had bought a new sports car, showing
that he saw his prognosis in a different way.
In general, it is important to remember that thyroid cancer is a
disease with rising incidence but decreasing mortality in Austria
and throughout the whole world [2,3], and this gap often leads
us to believe that a patient should not be ‘worried’ by their thyroid
cancer [1]. However, this is not very helpful, and physicians should
avoid telling patients ‘it could have been worse’ because the
patient is occupied with their own fate, asking why this happened
speciﬁcally to them, even when they appear to be trying to make
the best out of their situation.
Hypocalcaemia is an issue in QoL (even more than laryngeal
nerve palsy, when it occurs unilaterally), and the side effects of
radioiodine should be considered, although there is no risk of infer-
tility or genetic changes [4,5]. Most patients live long enough to
experience side effects and they can adversely affect QoL. For
example, xerostomia occurs in 10–20% of patients [6,7]. There is
a low risk of induction of a second malignant tumour by radioio-
dine, however, discussions centreing around this are controversial.
Data on this issue are heterogeneous but there is a probable hazard
ratio of 1.2 and females are more at risk than men.
Therefore, in summary, physicians should not give positive
diagnoses too readily, even if the statistics are in favour of good
news. It is easier to turn indifferent news into good news than vice
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schedule them as infrequently as possible. New drugs for treating
iodine-refractory tumours open new ﬁelds of possibilities and also
bring new side effects and new issues in medical training (if man-
agement is not done by oncologists). Physicians should be made
aware of all side effects; it is crucial to realise that an informed
patient tolerates much more than an uninformed patient.
The psychologist’s view – Dr. Eva Gamper
QoL encompasses a range of different concepts that are very
difﬁcult to put into practice. In health care, for many years the
solution to this was to restrict the measurement of QoL to some
of the symptoms, side-effects, and functioning, and to have these
items rated by physicians. However, it was realised that these
proxy ratings had limitations, such as a low inter-rater reliability
[8,9], a moderate agreement between proxy and patient reports
[10,11], and loss of information through interpretation and transla-
tion into medical terms [12]. Therefore, the use of patient reported
outcomes (PROs) as an additional source of information is increas-
ing in importance. According to the FDA, the deﬁnition of a PRO is
the report of a patient’s health condition coming directly from the
patient without any interpretation of the patient’s response by a
clinician or anyone else [13].
The core concept of PRO research is health-related QoL (HRQoL),
which comprises QoL domains that are inﬂuenced by the disease
and its treatment, i.e. HRQoL provides a measure that assesses a
patient’s psychological, social and somatic status [14] and is
expected to predict the effect of therapy. In thyroid cancer research
HRQoL measurement is still uncommon. This could be because
incident rates are small and it is very hard to collect sufﬁcient data.
However, it could also be due to a general opinion that QoL assess-
ment is less important in this patient group because, compared
with other cancer patients, they feel quite ‘well’. In addition, the
prognosis is good, so there is no ‘trade-off’ to be made between
survival and QoL when developing the treatment plan. However,
does a good prognosis coupled with favourable treatment options
(which might be the predominant features of thyroid cancer from
a physician’s point of view) really directly correlate with a good
patient-reported HRQoL? The information found in the literature
shows that patients that have to go through thyroid withdrawal
(i.e. endogenous TSH stimulation) clearly have an impaired
HRQoL, in physical as well as in psychosocial domains [15–17].
Furthermore, this patient group reports worse HRQoL than patients
with exogenous TSH stimulation [18–20]. There are conﬂicting
results concerning the inﬂuence of age and gender, and on if and
when patients in recurrence reach general population levels of
QoL [17,21–23]. Usually patients’ HRQoL decreases with age,
except for anxiety and depression which might be more pro-
nounced in younger patients. Furthermore, women report more
impairments than men, especially in the emotional dimensions.
The question of whether these age and gender patterns are thyroid
cancer speciﬁc or if they only reﬂect general response patterns
(which can also be found in the general population) has been
investigated by Singer et al. [24]. They found that after controlling
for the effects of age and gender, thyroid cancer patients still
reported signiﬁcantly more impairment than the German general
population in all but two domains (constipation and diarrhoea)
of the Quality of Life Questionnaire Core-30 (QLQ-C30: function-
ing: physical, role, emotional, social, cognitive; symptoms: fatigue,
nausea/vomiting, pain, dyspnea, sleep, appetite, constipation,
diarrhoea, ﬁnancial impact, and global QoL). In line with previous
ﬁndings, patients reported not only physical but severe psychoso-
cial problems, especially in role functioning. The QoL impairments
reported by thyroid cancer patients therefore cannot be attributed
to the fact that the majority of the patients are female and thatfemales generally tend to self-report more problems in
questionnaires.
In summary, there are two very different perspectives on thy-
roid cancer to be kept in mind. There is the medical expert, who
compares thyroid cancer with other cancers and might focus on
its good prognosis and favourable treatment options (with few side
effects and little social stigma). The expert may not even realise if
the patient is under-reporting symptoms, as a low level of impair-
ment would ﬁt the picture of the disease. Then there is the patient
who, although they need to know about the favourable prognosis
and treatment options, still has to deal with a cancer diagnosis
for the rest of their life. Additionally, the patient may also have
physical impairments never experienced before, and which may
erode their QoL. In the case of radioiodine treatment, s/he has to
deal with an unusual treatment including isolation for radioprotec-
tion, which might augment the feeling of being socially marginal-
ized as well. A range of emotional, social, and cognitive issues can
become very burdensome and sometimes patients even worry
about the appropriateness of these problems and may feel guilty
for taking psychological counselling help as they are expected to
be ‘alright’.
HRQoL assessment can contribute a great deal to bridging the
gap between these 2 perspectives. It adds value by incorporating
the patient perspective into both thyroid cancer research and
clinical practice. Patients are very willing to provide information
on many aspects of their QoL and this can help the physician to
understand patients’ concerns. Patients can be told what other
patients have perceived, and this can improve patient-centred care
and patient–physician communication. HRQoL assessment should
be encouraged; it is easy to perform and provides a lot of valuable
information.
The patient’s view – Dr. Heying Duan
Dr. Duan is a nuclear medicine expert, and has also been a
thyroid cancer patient, and therefore offered a unique perspective
on the disease. In October 2002, Dr. Duan found a lump in her neck.
She presented to her physician in January 2003 and was referred to
the nuclear medicine department. Two nodules in her thyroid were
discovered, which were classiﬁed as cold nodules by scintigraphy
and surgery was performed 2 weeks later. Histology revealed a
papillary thyroid carcinoma (pT2 without lymph node metastases).
The diagnosis and treatment inﬂuenced Dr. Duan to become a
nuclear medicine physician, and although she uses her personal
experience to reassure patients, she tries hard to maintain her
objective perspective.
In terms of QoL, when Dr. Duan had her ﬁrst appointment her
TSH was slightly above 4.0 lU/L, which would not normally be
treated, but she had severe fatigue. After surgery, the symptoms
were even worse: constant tiredness and feeling cold, even anxiety
attacks, and a range of other symptoms from total apathy to rest-
lessness. When diagnosed, one of the ﬁrst questions she had was
‘will I die soon?’ but Dr. Duan then rationalised the diagnosis and
tried not to blame herself or anyone else for the situation. She
was also afraid for her fertility, especially after radioiodine therapy.
Currently, Dr. Duan has no symptoms and her QoL is not affected at
all by her thyroid cancer.
In retrospect, Dr. Duan would have liked more information
about hypothyroidism and its related symptoms; at the time, she
did not understand if the symptoms were because of her diagnosis,
if they were permanent, or if they would change her personality.
Thankfully, the symptoms vanished following T4 substitution.
Dr. Duan felt that if the physicians had asked her more in depth
questions about her QoL when she was experiencing the
symptoms, she would have understood more clearly that her
experiences were related to the hypothyroidism as a result of her
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disappear.
Dr. Gamper added that even carrying out a QoL assessment has
the potential to improve patients’ QoL. Computer-assisted assess-
ments allow real-time feedback of the patient’s QoL proﬁle and
enable the physician to very quickly get an overall picture of the
patient’s health status and to structure the consultation accord-
ingly. QoL assessment can also help to overcome ‘white coat
silence’ – patients are often reluctant to discuss all of their symp-
toms with their physician because of time pressures and a desire to
not ‘burden’ the physician with emotional, social, or ‘minor’ health
problems. Thus, the questionnaire can be an effective and time-
saving communication tool, allowing the physician to quickly
appraise if a patient needs symptom management, more medical
information, or referral to psycho-oncologists or social workers.
It is very difﬁcult for patients to differentiate in HRQoL between
disease-related QoL issues and other general stresses. Dr. Duan
believes that the patient’s attitude to their diagnosis is paramount.
If the patient deals with the diagnosis in a positive way, they can
cope with the stresses and strains caused both by their disease
and by their everyday life much more easily.
Still, every person has a different way of coping and counter-
intuitively, thyroid cancer patients often have more severe psycho-
logical problems than patients with a poor prognosis, who are occu-
pied by juggling their treatment and side effects and are confronted
with trying to survive every day. Singer et al. [24] reported that thy-
roid cancer patients asked for psychological counselling support,
but there are no published outcome data. Psychologists with train-
ing in psychooncology do not need extra training to counsel thyroid
cancer patients because many of the issues that arise are common
to all cancer patients. They certainly need background knowledge
of thyroid cancer including treatment options and sequelae. In par-
ticular, the symptoms of hypo/hyperthyroidism as these might
easily be misinterpreted as psychiatric symptoms.
Whatever perspective is examined, it is key to understand that
QoL and emotional burden is not directly related to the severity of
the disease and that more research is needed to learn about thyroid
cancer patients’ needs. However, the three cases presented high-
light some fundamental points to be considered regarding the
treatment of thyroid cancer patients and their QoL:
 A ﬁrm diagnosis improves the quality of patients’ experi-
ences because speculative diagnosis can cause distress.
 Despite the physician giving a favourable prognosis at
diagnosis, the patient is likely to focus on the negative ele-
ments of the cancer diagnosis.
 QoL can be improved by explaining that the frequency of
laboratory tests and check-ups do not necessarily relate
to prognosis.
 Patients have very different coping strategies which have
an impact on their QoL.
 Even though there is decreasing mortality associated with
thyroid cancer, telling patients ‘it could have been worse’
should be avoided.
 Hypocalcaemia and the side effects of radioiodine can
adversely affect QoL.
 It is easier to turn indifferent news into good news than
vice versa.
 A patient, who is informed, and aware of all of the side
effects of treatment, is likely to be more tolerant of treat-
ment than an uniformed patient.
 The use of PROs as an additional source of information is of
increasing importance.
 HRQoL measurement in thyroid cancer maybe uncommon
because of the misconception that QoL is less important
in this group of patients than in other cancer patients. HRQoL assessment can contribute to bridging the gap
between physicians and patients; improving communica-
tion between them and potentially improving patients’
QoL.
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